- Home
- NDLS vs ATRA Comparison
NDLS vs ATRA Comparison
Compare NDLS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- ATRA
- Stock Information
- Founded
- NDLS 1995
- ATRA 2012
- Country
- NDLS United States
- ATRA United States
- Employees
- NDLS N/A
- ATRA N/A
- Industry
- NDLS Restaurants
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDLS Consumer Discretionary
- ATRA Health Care
- Exchange
- NDLS Nasdaq
- ATRA Nasdaq
- Market Cap
- NDLS 45.2M
- ATRA 42.9M
- IPO Year
- NDLS 2013
- ATRA 2014
- Fundamental
- Price
- NDLS $0.90
- ATRA $7.56
- Analyst Decision
- NDLS Strong Buy
- ATRA Buy
- Analyst Count
- NDLS 2
- ATRA 5
- Target Price
- NDLS $3.00
- ATRA $17.75
- AVG Volume (30 Days)
- NDLS 79.4K
- ATRA 48.8K
- Earning Date
- NDLS 05-07-2025
- ATRA 05-20-2025
- Dividend Yield
- NDLS N/A
- ATRA N/A
- EPS Growth
- NDLS N/A
- ATRA N/A
- EPS
- NDLS N/A
- ATRA N/A
- Revenue
- NDLS $495,670,000.00
- ATRA $128,940,000.00
- Revenue This Year
- NDLS $4.57
- ATRA N/A
- Revenue Next Year
- NDLS $1.29
- ATRA N/A
- P/E Ratio
- NDLS N/A
- ATRA N/A
- Revenue Growth
- NDLS N/A
- ATRA 1404.02
- 52 Week Low
- NDLS $0.55
- ATRA $5.01
- 52 Week High
- NDLS $2.36
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- NDLS 38.19
- ATRA 58.39
- Support Level
- NDLS $0.81
- ATRA $6.90
- Resistance Level
- NDLS $1.09
- ATRA $8.65
- Average True Range (ATR)
- NDLS 0.07
- ATRA 0.61
- MACD
- NDLS 0.00
- ATRA 0.06
- Stochastic Oscillator
- NDLS 21.07
- ATRA 64.26
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).